{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"RenovoRx Establishes RenovoCath\u00ae Medical Advisory Board - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"0BAdfgFBGT\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-establishes-renovocath-medical-advisory-board\/\">RenovoRx Establishes RenovoCath\u00ae Medical Advisory Board<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-establishes-renovocath-medical-advisory-board\/embed\/#?secret=0BAdfgFBGT\" width=\"600\" height=\"338\" title=\"&#8220;RenovoRx Establishes RenovoCath\u00ae Medical Advisory Board&#8221; &#8212; Market Newsdesk\" data-secret=\"0BAdfgFBGT\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"Advisory Board Members Will Provide Strategic Clinical Insights to Further Advance the TAMP\u2122 Therapy Platform in Clinical Indications of High Unmet Medical Need MOUNTAIN VIEW, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) &#8212; RenovoRx, Inc. (\u201cRenovoRx\u201d or the \u201cCompany\u201d) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath\u00ae, a patented, FDA-cleared drug-delivery device, today announced the formation of a dedicated RenovoCath Medical Advisory Board (\u201cMAB\u201d) to support its clinical and strategic initiatives. The MAB brings together leading US interventional radiology experts to provide strategic clinical insights that further advance the TAMP (Trans-Arterial Micro-Perfusion) therapy platform in clinical indications of high unmet medical need. The MAB compliments the Company\u2019s esteemed and long-standing Scientific Advisory Board that provides &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MTY3MiM3NDE3NDg3IzIyMDkxNTc="}